New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ

New York State Teachers Retirement System decreased its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 20.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,854 shares of the specialty pharmaceutical company’s stock after selling 9,223 shares during the quarter. New York State Teachers Retirement System’s holdings in Jazz Pharmaceuticals were worth $4,594,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of JAZZ. Farther Finance Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after acquiring an additional 234 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 30.7% during the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 154 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new position in Jazz Pharmaceuticals in the 1st quarter worth $90,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on JAZZ. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Bank of America boosted their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, JPMorgan Chase & Co. lowered their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research report on Monday, October 27th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $205.67.

Jazz Pharmaceuticals Stock Down 1.0%

NASDAQ JAZZ opened at $169.41 on Friday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99. The stock has a market capitalization of $10.29 billion, a PE ratio of -27.91, a PEG ratio of 0.76 and a beta of 0.27. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.65 and a quick ratio of 1.44. The business’s 50-day moving average is $167.01 and its 200 day moving average is $139.53.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Heather Ann Mcsharry sold 3,415 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the transaction, the director directly owned 20,449 shares of the company’s stock, valued at approximately $3,635,423.22. The trade was a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the transaction, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This represents a 10.29% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 123,791 shares of company stock worth $21,991,850. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.